Cigna Group (The) (CI) Valuation

From a value investing perspective, Cigna's current price of $270.36 presents a compelling valuation case. The GoodMoat target of $3,721.77 implies a massive margin of safety of approximately 85%, which falls into the 'Deeply Undervalued' band (>40%) per the framework's DCF guidelines. This indicates the market price is a substantial discount to the estimated intrinsic value. The stock's forward P/E of 12.1x is a key metric for a mature, profitable healthcare insurer. This multiple is significantly lower than the broader healthcare sector average, which often trades above 20x, and is also low relative to Cigna's own historical averages and its double-digit revenue growth of 10.4%. The valuation is further supported by a robust Free Cash Flow Yield of 11.6%, which is highly favourable and suggests the company is generating ample cash relative to its market value. While the low profit margins of 2-3% are typical for the managed care industry and reflect its service-based model, the combination of a low P/E, high FCF yield, and significant discount to the target price suggests the stock is cheap relative to its underlying business quality and financial strength. The primary question for an investor is not valuation, but the durability of the company's competitive moat and its growth trajectory, which would be assessed in prior framework steps.